Psoriasis treatment: a literature review


  • Mariana Elguezabal Riojas Department of Internal Medicine, Hospital General de Zona, IMSS, Guadalupe, Nuevo León, México



Psoriasis, Treatment, Chronic skin disease


Psoriasis is a chronic skin disease that affects millions of people worldwide. Its etiology is not yet fully understood, but it is thought to be related to a combination of genetic, immunological and environmental factors. In this literature review article, several relevant scientific studies and publications will be analyzed to provide an overview of psoriasis treatment. Aspects such as epidemiology, the significance of the disease, the theoretical framework that includes definition, diagnosis, treatment and complications will be addressed, and conclusions based on the available evidence will be presented.


Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, et al. Prevalence of most common skin diseases in Europe: a population‐based study. J Euro Acad Dermatol Venereol. 2022;36(7):1088-96.

Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023.

Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunological Rev. 2017;278(1):246-62.

Campalani E, Barker JNWN. The clinical genetics of psoriasis. Current Genomics, 2005;6(1):51-60.

Johnson MAN, Armstrong AW. Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clinical Rev Allergy Immunol. 2013;44:166-72.

Pezzolo E, Cazzaniga S, Colombo P, Chatenoud L, Naldi L. Psoriasis incidence and lifetime prevalence: suggestion for a higher mortality rate in older age-classes among psoriatic patients compared to the general population in Italy. Acta dermato-venereologica. 2019;99(4):400-3.

Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019; 80(1):27-40.

Kimball AB, Wu EQ, Guérin A, Andrew PY, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651-7.

Reich K, Hüffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*‐857 independent of the PSORS1 risk allele. Arthritis Rheumatism, 2017;56(6):2056-64.

Lin ZM, Ma M, Li H, Qi Q, Liu YT, Yan YX, et al. Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17. Pharmacological Res. 2018;129, 443-52.

Mrowietz U. Implementing treatment goals for successful long‐term management of psoriasis. J Euro Acad Dermatol Venereol. 2012;26:12-20.

Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1):S39-S49.

Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001;26(4):343-50.

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.

Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Therapy. 2016;6:1-12.






Review Articles